Register
Login:
Share:
Email Facebook Twitter

Please take part in our survey It takes 2 minutes and you could win an Apple iPad Air 2 (Terms and conditions apply). Dismiss Message
Add Immupharma to quick picks

Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 53.00Bid: 52.00Ask: 54.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 2.00Spread as %: 3.85%Open: 54.50High: 54.50Low: 53.00Yesterday’s Close: 53.00
InfoCFDs vs Share Trading - Download your Free Guide from London South East Markets
When trading CFDs, Forex, and Spread bets, it is possible to lose more than your initial deposit.


Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
53.00

Share Price SpacerBid
52.00

Share Price SpacerAsk
54.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
37,881

Share Price SpacerOpen
54.50

Share Price SpacerHigh
54.50

Share Price SpacerLow
53.00

Share Price SpacerClose
53.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 88.62m £46.97m 5,000

52 Week High 66.00 52 Week High Date 3-NOV-2014
52 Week Low 41.50 52 Week Low Date 9-JUN-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
18 35,953 1,928 -11.726 -4.52 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

23-Jan-15
16:21:11
52.00
2,200
Sell* 
52.00
54.00
1,144
Trade Type:
Ordinary

23-Jan-15
15:19:48
53.875
928
Buy* 
53.00
54.00
499.96
Trade Type:
Ordinary

23-Jan-15
14:31:03
53.90
1,000
Buy* 
53.00
54.00
539.00
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
23-Jan-12Buy
Trade Notifier Information for Immupharma
Franco Di Muzio held the position of Non-Executive Director at Immupharma at the time of this trade.
 Franco Di Muzio
81GBX60,9500
View more Immupharma directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Fri 16:34
leas
boom
53.50
No Opinion

Good afternoon boom. Sorry, missed your post at 1608. I have not had time to fully digest the RNS yesterday and DD's comments. I have promised myself a year out after retiring and planning some holiday adventures for my family. Cannot see the sp falling below my average now so I am happy to let it ride. More importantly, I hope the trial is successful, not because of any potential revenue but for those suffering the effects of the disease.
Fri 16:11
boomorbust
leas
53.50
No Opinion

Of course Dimitri Dimitriou has previously stated that there are institutional investors who will not invest until a bio has a phase III product and he strongly hinted that he expected further ii investment once phase III was underway. We will see!!
Fri 16:11
leas
RE: Market
53.50
No Opinion

An observation from yesterday's trades. There was a number of consecutive 1000 share trades yesterday that dragged us back to the current level. Small pi chunks but seemed a little odd that they were all closely timed. Probably coincidental but worth a ponder.
Fri 16:08
boomorbust
Phase III
53.50
No Opinion

A tiny bit more detail. According to Simbec-Orion the study will be recruiting in between 4 and 8 European countries as well as the US. They have previously carried out both phase II and III trials for lupus. http://www.outsourcing-pharma.com/Clinical-Development/CRO-Simbec-Orion-land-Phase-III-lupus-trial-with-fast-tracked-compound
Fri 16:05
leas
RE: Market
53.50
No Opinion

Dibs, have to agree. From memory Aviva took up a placing at or about the current sp back in November. Cannot see them willing to pay that price if they were not aware of something that was not in the public domain. These guys all p155 in the same pot so I would expect a placing at a similar price. Things moving forward now and fully expect a rise from any placing level as the trial progress's. The potential returns on success is huge and cannot see a big pharma ignoring this. Fingers crossed for news being more fluid now, not just for investors but those affected by lupus. Guys, enjoy your weekend.
Fri 12:46
Dibs61
Market
53.50
No Opinion

Now waiting for funding details. Conspicuous lack of buyers strongly suggests there will be a placing. However what we don't know is what the strike price will be and the overall structure of the deal. Might be a nice surprise, one of those rare placings that provides a positive reaction (which we haven't yet enjoyed from yesterdays announcement)

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.